-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
As China Traditional Chinese Medicine Holdings (HKG:570) Rises 5.2% This Past Week, Investors May Now Be Noticing the Company's Five-year Earnings Growth
As China Traditional Chinese Medicine Holdings (HKG:570) Rises 5.2% This Past Week, Investors May Now Be Noticing the Company's Five-year Earnings Growth
Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results between individual stocks. So we wouldn't blame long term China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) shareholders for doubting their decision to hold, with the stock down 28% over a half decade. Shareholders have had an even rougher run lately, with the share price down 15% in the last 90 days.
Although the past week has been more reassuring for shareholders, they're still in the red over the last five years, so let's see if the underlying business has been responsible for the decline.
See our latest analysis for China Traditional Chinese Medicine Holdings
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
While the share price declined over five years, China Traditional Chinese Medicine Holdings actually managed to increase EPS by an average of 12% per year. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Or possibly, the market was previously very optimistic, so the stock has disappointed, despite improving EPS.
Because of the sharp contrast between the EPS growth rate and the share price growth, we're inclined to look to other metrics to understand the changing market sentiment around the stock.
The steady dividend doesn't really explain why the share price is down. It's not immediately clear to us why the stock price is down but further research might provide some answers.
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
SEHK:570 Earnings and Revenue Growth August 18th 2022We know that China Traditional Chinese Medicine Holdings has improved its bottom line lately, but what does the future have in store? So it makes a lot of sense to check out what analysts think China Traditional Chinese Medicine Holdings will earn in the future (free profit forecasts).
What About Dividends?
It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. As it happens, China Traditional Chinese Medicine Holdings' TSR for the last 5 years was -20%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!
A Different Perspective
While it's never nice to take a loss, China Traditional Chinese Medicine Holdings shareholders can take comfort that , including dividends,their trailing twelve month loss of 15% wasn't as bad as the market loss of around 17%. Unfortunately, last year's performance may indicate unresolved challenges, given that it's worse than the annualised loss of 4% over the last half decade. Whilst Baron Rothschild does tell the investor "buy when there's blood in the streets, even if the blood is your own", buyers would need to examine the data carefully to be comfortable that the business itself is sound. It's always interesting to track share price performance over the longer term. But to understand China Traditional Chinese Medicine Holdings better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for China Traditional Chinese Medicine Holdings you should know about.
But note: China Traditional Chinese Medicine Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
理想情況下,你的整體投資組合應該超過市場平均水平。但在任何投資組合中,個股之間的結果都會喜憂參半。所以我們不會責怪長期中國中醫藥控股有限公司(HKG:570)股東對他們持有股票的決定表示懷疑,該股在過去五年中下跌了28%。股東們最近的表現更加艱難,股價在過去90天裏下跌了15%。
儘管過去一週對股東來説更令人安心,但他們在過去五年仍處於虧損狀態,所以讓我們看看基礎業務是否對股價下跌負有責任。
查看我們對中國中醫藥控股公司的最新分析
在他的文章中格雷厄姆和多德斯維爾的超級投資者沃倫·巴菲特描述了股價並不總是理性地反映一家企業的價值。一種不完美但簡單的方法來考慮市場對一家公司的看法是如何改變的,那就是將每股收益(EPS)的變化與股價走勢進行比較。
雖然股價在過去五年裏有所下降,但中國中醫藥控股實際上成功地增加平均每年以12%的速度增長。考慮到股價的反應,人們可能會懷疑,每股收益不是這段時間內業務表現的良好指南(可能是因為一次性的虧損或收益)。也有可能,此前市場非常樂觀,因此儘管每股收益有所改善,但該股仍令人失望。
由於每股收益增長率和股價增長率之間的鮮明對比,我們傾向於通過其他指標來了解圍繞股票不斷變化的市場情緒。
穩定的股息並不能真正解釋股價下跌的原因。我們目前還不清楚為什麼股價會下跌,但進一步的研究可能會提供一些答案。
您可以在下圖中看到收益和收入隨時間的變化(單擊圖表查看確切的值)。
聯交所:570盈利及收入增長2022年8月18日我們知道,中國中醫藥控股公司最近提高了利潤,但未來會是什麼樣子?因此,看看分析師認為中國中醫藥控股未來的盈利情況(免費盈利預測)是很有意義的。
那股息呢?
重要的是要考慮任何給定股票的總股東回報以及股價回報。TSR是一種回報計算,計入了現金股息的價值(假設收到的任何股息都進行了再投資),以及任何貼現融資和剝離的計算價值。可以説,TSR更全面地描繪了一隻股票產生的回報。碰巧的是,中國中醫藥控股最近5年的TSR為-20%,超過了前面提到的股價回報。這在很大程度上是其股息支付的結果!
不同的視角
雖然虧損從來都不是好事,但中國中醫藥控股的股東可以感到欣慰的是,包括股息在內,他們過去12個月15%的虧損沒有市場虧損17%左右那麼糟糕。不幸的是,去年的表現可能預示着尚未解決的挑戰,因為它比過去五年4%的年化損失更糟糕。雖然羅斯柴爾德男爵確實會告訴投資者“在街上有血的時候買入,即使血是你自己的”,但買家需要仔細檢查數據,才能確信業務本身是穩健的。跟蹤股價的長期表現總是很有趣的。但要更好地瞭解中國中醫藥控股,我們還需要考慮許多其他因素。例如,考慮一下風險。每家公司都有它們,我們已經發現中國中醫藥控股有限公司的1個警告標誌你應該知道。
但請注意:中國中醫藥控股可能不是最值得買入的股票。所以讓我們來看看這個免費過去有盈利增長(以及進一步增長預測)的有趣公司名單。
請注意,本文引用的市場回報反映了目前在香港交易所交易的股票的市場加權平均回報。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧